2011
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings Of The National Academy Of Sciences Of The United States Of America 2011, 108: 16723-16728. PMID: 21933959, PMCID: PMC3189057, DOI: 10.1073/pnas.1110814108.Peer-Reviewed Original ResearchConceptsNY-ESO-1-seropositive patientsNY-ESO-1 antibodyT cell responsesClinical benefitImmune responseIpilimumab treatmentNY-ESO-1 immune responsesNY-ESO-1 serum antibodyTumor antigen-specific immune responsesCytotoxic T-lymphocyte antigen-4NY-ESO-1 immunityT-lymphocyte antigen-4Antigen-specific immune responsesIpilimumab-treated patientsAdvanced melanoma patientsAdvanced metastatic melanomaCancer/testis antigensSubset of patientsNY-ESO-1Significant survival advantageCD8 responsesAdoptive transferClinical outcomesMelanoma patientsProspective study
2008
Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions
Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Modern Pathology 2008, 21: 1121-1129. PMID: 18552823, PMCID: PMC2570478, DOI: 10.1038/modpathol.2008.100.Peer-Reviewed Original ResearchAntigens, NeoplasmBiomarkers, TumorCell NucleusDiagnosis, DifferentialFluorescent Antibody Technique, IndirectGp100 Melanoma AntigenHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesMelanomaMelanoma-Specific AntigensMembrane GlycoproteinsNeoplasm ProteinsNevus, PigmentedSkin NeoplasmsTissue Array Analysis
1985
Primary Melanoma Cells of the Vertical Growth Phase: Similarities to Metastatic Cells2
Herlyn M, Balaban G, Bennicelli J, Guerry D, Halaban R, Herlyn D, Elder D, Maul G, Steplewski Z, Nowell P, Clark W, Koprowski H. Primary Melanoma Cells of the Vertical Growth Phase: Similarities to Metastatic Cells2. Journal Of The National Cancer Institute 1985, 74: 283-289. PMID: 3856042, DOI: 10.1093/jnci/74.2.283.Peer-Reviewed Original ResearchConceptsVertical growth phaseMetastatic melanoma cellsMelanoma cellsMetastatic lesionsPrimary melanomaMetastatic cellsMelanoma-associated antigensMixed hemadsorption assaysPrimary melanoma cellsLong-term cultured cellsMetastatic melanoma cell linesGrowth phaseMelanoma cell linesRadial growth phaseMalignant melanomaNude micePopulation-doubling timeNonrandom abnormalitiesFlow cytometryHemadsorption assaysMonoclonal antibodiesMelanomaPatientsCell linesLesions